Heart Failure with Reduced Ejection Fraction

Correct Answer: D

### TLDR **Angiotensin-converting enzyme (ACE) inhibitors** are a cornerstone of heart failure with reduced ejection fraction (HFrEF) therapy, uniquely proven to reduce mortality. While other medications manage symptoms or prevent complications, ACE inhibitors directly impact long-term survival by favorably remodeling the cardiovascular system. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | |:---|:---|:---|:---| | Digoxin | Na+/K+-ATPase inhibition; ↑ myocardial contractility; ↓ HR. | Symptom control (dyspnea, fatigue); no mortality benefit. | Symptomatic only; narrow therapeutic index; no survival advantage. | | Diuretics | Increase sodium/water excretion; reduce preload and congestion. | Primary treatment for fluid overload symptoms (dyspnea, edema). | Symptom relief only; no evidence for mortality reduction. | | Anticoagulants | Prevent clot formation (e.g., in AFib, prior VTE). | Indicated for specific comorbid conditions; not routine for all HFrEF. | Prevent thromboembolism, not direct HFrEF mortality reduction. | | **Angiotensin-converting enzyme (ACE) inhibitors** | Block RAAS; prevent vasoconstriction, sodium/water retention, remodeling. | Foundational therapy for HFrEF; reduces morbidity and mortality. | Proven to reduce all-cause mortality and hospitalizations in HFrEF. | ### Detailed Breakdown The question asks about medications associated with a reduced mortality rate in heart failure. This targets guideline-directed medical therapies (GDMT) that have shown significant survival benefits in clinical trials. **Angiotensin-converting enzyme (ACE) inhibitors** are correct because they are foundational therapy for HFrEF and have consistently demonstrated a reduction in all-cause mortality and hospitalizations. Their mechanism involves blocking the conversion of angiotensin I to angiotensin II, leading to vasodilation, decreased aldosterone secretion, reduced sympathetic activity, and inhibition of cardiac remodeling. This multifaceted action improves cardiac function and prevents disease progression, directly translating to improved survival. Let's examine why the other options are incorrect regarding mortality reduction: * **Digoxin** is a positive inotropic agent that can improve symptoms, reduce hospitalizations for heart failure, and slow the heart rate in patients with concomitant atrial fibrillation. However, clinical trials have not shown a mortality benefit for digoxin in HFrEF; its role is primarily for symptom management. * **Diuretics** (e.g., furosemide, torsemide) are crucial for managing symptoms of fluid overload in HFrEF, such as dyspnea and peripheral edema. They reduce intravascular volume, thereby decreasing preload and congestion. While essential for symptomatic relief and improving quality of life, diuretics do not alter the underlying disease progression or reduce mortality in HFrEF. * **Anticoagulants** (e.g., warfarin, direct oral anticoagulants) are indicated for specific conditions that often coexist with HFrEF, such as atrial fibrillation, a history of thromboembolic events (e.g., stroke, pulmonary embolism), or documented left ventricular thrombus. They prevent clot formation and subsequent complications. However, anticoagulants are not routinely recommended for all HFrEF patients without these specific indications, and they do not directly reduce the overall mortality associated with heart failure itself. Their benefit is in preventing thromboembolic events, not in modifying the HFrEF disease process that leads to mortality.